CTNM

Rating neutralTentativeAI Memo

Contineum Therapeutics

As of 2026-10-26/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-26 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

PROPEL-IPF enrollment progress • 2027-06-30

Base target: $9 / p=45% prob

Biggest risk

The partnered MDD trial missed its primary endpoint, leaving PIPE-307's next step to J&J's discretion. PIPE-791 remains an unproven Phase 2 asset, and the mixed dose results in BMY's later-stage IPF trial do not establish CTNM-specific efficacy. [#8-K-2026-09-14] Contineum release Bristol Myers release

Invalidation

Break below $4 or thesis failure.

What would change my mind?

PIPE-791 could benefit if its own IPF trial validates the LPA1 mechanism. Contineum reported $236.6 million of cash, equivalents and marketable securities at June 30 and projected runway through mid-2029, beyond its estimated IPF trial completion. That projection remains subject to spending and trial execution. [#SEC-8K-2026-07-30] SEC-filed company release

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-26

Base target

p=45%

Bull target

$16

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

J&J decision after MOONLIGHT-1 miss
PIPE-791 Phase 2 IPF efficacy result
PIPE-791 could benefit if its own IPF trial validates the LPA1 mechanism.

BearKey bullets

Clinical-stage concentration and a loose valuation peer set make CTNM vulnerable to large event-driven price moves.
J&J may curtail PIPE-307 development after the MOONLIGHT-1 primary-endpoint miss; no decision timing was disclosed.
[#8-K-2026-09-14]

WatchKey bullets

PROPEL-IPF enrollment progress

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $9 (p=45%)

Target spread vs base: +78% / -61%

Scenario probabilities

Bull Target: $16 (p=25%)Base Target: $9 (p=45%)Bear Target: $4 (p=30%)

Commentary

News tone is negative after the September MDD trial miss and October IPF class read-through. Investing.com reported a roughly 25% CTNM decline on October 12 after an initial premarket rise; the packet's October 23 anchor is $8.31. The same coverage reported a Stifel Buy reiteration, not evidence of broad upward estimate revisions. No reliable social, options, short-interest or employee metrics were supplied; the zero fields above indicate unavailable data, not neutral readings.

As of 2026-10-26 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

J&J decision after MOONLIGHT-1 miss
PIPE-791 Phase 2 IPF efficacy result

Scenarios

Bull Target (Scenario probability)

$16 / p=25% prob

Base Target (Scenario probability)

$9 / p=45% prob

Bear Target (Scenario probability)

$4 / p=30% prob

Analysis 2026-10-26 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.45

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-06-30
PROPEL-IPF enrollment progress
PIPE-791's roughly 324-patient Phase 2 IPF trial is Contineum's lead company-run program. The company reported more than 55 sites online in eight countries in July; subsequent enrollment progress or delay would change confidence in execution. The date is an estimate, not company guidance. [#SEC-8K-2026-07-30] SEC-filed company release
Prob 65.00% • Move 15.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

J&J decision after MOONLIGHT-1 miss
2027-03-31
The J&J-run Phase 2 MDD trial missed its Day 5 primary efficacy endpoint. Contineum reported no new safety signal; J&J is evaluating exploratory data before deciding next steps. No decision date has been announced, so the date shown is a monitoring estimate. [#8-K-2026-09-14] SEC-filed company release
Prob 60% • Move -15% • Priced-in 65%

Long-term Catalysts

Months to a year

PIPE-791 Phase 2 IPF efficacy result
2028-06-30
PROPEL-IPF measures change in forced vital capacity through week 26. A persuasive result could establish PIPE-791 on its own evidence; failure would be consequential for the lead asset. The modeled date approximates the company's estimated trial completion around mid-2028, not a confirmed topline announcement. [#SEC-8K-2026-07-30] SEC-filed company release
Prob 45% • Move 55% • Priced-in 20%

Risks

Clinical-stage concentration and a loose valuation peer set make CTNM vulnerable to large event-driven price moves.
J&J may curtail PIPE-307 development after the MOONLIGHT-1 primary-endpoint miss; no decision timing was disclosed. [#8-K-2026-09-14]
PROPEL-IPF enrollment, efficacy, safety and regulatory outcomes remain uncertain; another company's LPA1 result cannot substitute for PIPE-791 data. [#SEC-8K-2026-07-30]
The projected mid-2029 cash runway is management's estimate and could shorten if spending or trial requirements rise. [#SEC-8K-2026-07-30]

Peers

Symbol	Summary
BMY	Direct LPA1/IPF mechanism comparator, not a valuation peer. Bristol Myers reported that admilparant's Phase 3 ALOFT-IPF trial met its primary endpoint at 60 mg but not 120 mg. This supports class plausibility without proving PIPE-791 efficacy; BMY is much larger and further along in development. Bristol Myers release
XFOR	Packet-supplied small-cap biotechnology size comparator only. No shared indication or mechanism is established, so its valuation should not be used as a direct PIPE-791 benchmark.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-26

Loading AI feed…

Symbol

Summary

BMY

Direct LPA1/IPF mechanism comparator, not a valuation peer. Bristol Myers reported that admilparant's Phase 3 ALOFT-IPF trial met its primary endpoint at 60 mg but not 120 mg. This supports class plausibility without proving PIPE-791 efficacy; BMY is much larger and further along in development. Bristol Myers release

XFOR

Packet-supplied small-cap biotechnology size comparator only. No shared indication or mechanism is established, so its valuation should not be used as a direct PIPE-791 benchmark.